Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 171Recruiting 101Active not recruiting 53Unknown 51Terminated 49Withdrawn 16Not yet recruiting 11Enrolling by invitation 3Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 84Other hematologic neoplasm 44Lymphoid 41Breast 41CNS 39Genitourinary 35Thoracic 31Other solid neoplasm 24Gynecologic 21Dermatologic 21Tumor-Agnostic 18Head & Neck 18Sarcoma 17Myeloid 14Plasma cell 9Other 5Classical hematology 4Endocrine 3Other neoplasm 1NET 1

Conditions

Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × NET × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡